← Back to Search

ePRO Reporting Methods for Multiple Myeloma

N/A

Recruiting

Research Sponsored by Thomas Jefferson University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Diagnosis of MM

Patients undergoing an autologous stem cell transplant will be enrolled after their transplant

Timeline

Screening 3 weeks

Treatment Varies

Follow Up at 6 months

Awards & highlights

Study Summary

This trial evaluates patient satisfaction w/text messaging (TXT-Chatbot) vs patient portal (MyChart/Patient Portal) for reporting symptoms among those with multiple myeloma, a hematologic cancer. Results may help understand patient preferences for ePRO collection.

Who is the study for?

This trial is for adults with Multiple Myeloma who can use text messaging or have internet access, understand English, and are post-autologous stem cell transplant. It excludes those under 18 or with documented cognitive impairment.Check my eligibility

What is being tested?

The study compares patient satisfaction using a text message-based system (TXT-Chatbot) versus a patient portal (MyChart/Patient Portal) for reporting symptoms in real-time among Multiple Myeloma patients.See study design

What are the potential side effects?

Since this trial involves behavioral interventions like TXT-Chatbot and survey administration rather than medications, traditional side effects are not applicable. However, participants may experience inconvenience or privacy concerns.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been diagnosed with multiple myeloma (MM).

Select...

I will join the study after my stem cell transplant using my own cells.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ at 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~at 6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and at 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Choice of TXT-Chatbot

Number of completed electronic Patient-Reported Outcome (ePRO) responses

Secondary outcome measures

Overall Satisfaction Scores Using the Client Satisfaction Questionnaire (CSQ-8)

Trial Design

2Treatment groups

Experimental Treatment

Group I: Group II (MyChart/Patient Portal)Experimental Treatment5 Interventions

Patients receive an email notification and complete surveys through MyChart/Patient Portal Q2W for 6 weeks.

Group II: Group I (TXT-Chatbot )Experimental Treatment5 Interventions

Patients receive a text message notification and complete surveys through TXT-Chatbot Q2W for 6 months.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Behavioral Intervention

2021

Completed Phase 4

~3740

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Thomas Jefferson UniversityLead Sponsor

445 Previous Clinical Trials

145,239 Total Patients Enrolled

4 Trials studying Multiple Myeloma

156 Patients Enrolled for Multiple Myeloma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To what number has recruitment been capped for this clinical experiment?

"Affirmative. Clinicaltrials.gov conveys that this medical trial, which was first unveiled on June 13th 2023, is currently seeking participants. An estimated 200 individuals must be recruited from 1 location for the study to continue."

Answered by AI

Are there any available slots left in this trial for new participants?

"This clinical trial is currently accepting participants, as indicated by its listing on the official website. The first posting took place June 13th 2023 and was last edited September 11th of the same year."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Two Implementation Strategies for the Collection of Electronic Patient-Reported Outcomes Among Patients With Multiple Myeloma

2023. "Two Implementation Strategies for the Collection of Electronic Patient-Reported Outcomes Among Patients With Multiple Myeloma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06041698.